OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
On March 16, 2023, Catalent announced that it has signed a licensing agreement with India-based Bhami Research Laboratory (BRL) that will provide Catalent with access to BRL’s formulation technology. Using the technology, Catalent intends to develop formulations that will help enable the subcutaneous delivery of high-concentration biologics. Financial terms of the agreement were not disclosed.
The agreement authorizes Catalent to collaborate with its customers to evaluate BRL’s formulation technology so that Catalent and its customers can explore ways to reduce viscosity and deliver high-concentration biologic products. BRL’s technology is applicable to a wide range of monoclonal antibodies and fusion proteins. Successful programs could be integrated into Catalent’s formulation and manufacturing services at scale.
According to a Catalent press release, the subcutaneous delivery of small volume, low viscosity biotherapeutics can provide superior patient benefits over traditional intravenous injections. Such benefits include improved access to healthcare, reduced need for hospitalization and overall treatment cost, and the opportunity to employ new delivery technologies, such as auto-injectors.
“The patented, high-concentration, low-viscosity protein drug delivery platform has been designed to make patient care convenient, affordable, and safe,” said Bhami Shenoy, co-founder and chief scientific officer of BRL, in the press release.
“This agreement allows Catalent Biologics to offer its customers a novel patented formulation that may be evaluated for enabling the delivery of high-concentration therapies by reducing viscosity,” said Julien Meissonnier, Catalent’s chief scientific officer, in the release. “The potential for maintaining the stability of a drug with the convenience of a pre-filled syringe or auto-injector could have a significant impact on reducing the barriers to subcutaneous delivery of therapies and improving the patient experience.”